Charles Schwab Investment Management Inc. Purchases 7,243 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Charles Schwab Investment Management Inc. lifted its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 264,675 shares of the company’s stock after acquiring an additional 7,243 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Design Therapeutics were worth $1,633,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Paloma Partners Management Co acquired a new stake in Design Therapeutics in the third quarter worth about $64,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Design Therapeutics in the 4th quarter valued at about $74,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Design Therapeutics during the 3rd quarter worth approximately $71,000. MetLife Investment Management LLC bought a new stake in shares of Design Therapeutics during the third quarter worth approximately $104,000. Finally, PDT Partners LLC raised its stake in shares of Design Therapeutics by 33.1% during the third quarter. PDT Partners LLC now owns 36,099 shares of the company’s stock worth $194,000 after buying an additional 8,972 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Stock Performance

Shares of DSGN stock opened at $4.21 on Friday. The firm’s 50 day moving average price is $4.69 and its two-hundred day moving average price is $5.34. Design Therapeutics, Inc. has a 52-week low of $3.15 and a 52-week high of $7.77. The stock has a market cap of $238.97 million, a PE ratio of -4.95 and a beta of 1.77.

Design Therapeutics (NASDAQ:DSGN) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. As a group, sell-side analysts predict that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Design Therapeutics Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.